rev-slider

LET’S HACK THE CODE!

Just six decades after Orville and Wilbur Wright launched the aviation age, President Kennedy pronounced a moonshot: fly people to the moon and back.  Eight years later, the mission was accomplished.  Now, six decades after James Watson and Francis Crick discovered the code of life, it is time to embark on another historic mission: hack the code of life and cure aging.

 

The Palo Alto Longevity Prize (the “Prize”) is a $1 million life science competition dedicated to ending aging.  Ours is one of a growing number of initiatives around the world pursuing this goal—the more shots on goal the better.  Through an incentive prize, our specific aim is to nurture innovations that end aging by restoring the body’s homeostatic capacity and promoting the extension of a sustained and healthy lifespan.

PALO ALTO PRIZE – TEAM APPROACH

There are two prizes available and teams may compete for one or both prizes:

• A $500,000 Homeostatic Capacity Prize will be awarded to the first team to demonstrate that it can restore homeostatic capacity (using heart rate variability as the surrogate measure) of an aging reference mammal to that of a young adult.

• A $500,000 Longevity Demonstration  Prize will be awarded to the first Team that meets all the requirements of the Prize Requirements as determined by the Judging Panel in its sole discretion, including extending the mean lifespan of a wild-type mammalian intervention cohort by 50% relative to acceptable published natural history of untreated norms in a statistically significant (p<.05) manner, using a Statistical Model (as defined and approved in the official “Competition Agreement”). The intervention and control cohorts should be age and gender matched and should include an equal number of males and females.   If you would like more details on the Prize Requirements please use the contact form at the bottom of this page

Each team participating in the Prize is responsible for funding 100% of its participation in the Prize including all research and development costs and publishing its work and/or the reproduction of results. To enable a rapid commercial path forward for the innovations, the sponsor of the Prize will be contributing an existing pool of relevant intellectual property to the Prize effort.

PALO ALTO PRIZE – PERSONAL STORIES

Sign up today!

Innovation happens in the most magical ways and often it requires people from outside the field of study to see the challenge with a new perspective. If you are ready to sign up as a team to compete – please fill out an Intent to Participate Application If you have any questions or if you would like to review the Prize rules, please let us know.

LET’S DO THIS!

“There is a possibility that the timed switch from a functional ANS to a dysfunctional ANS may be a key underlying mechanism of chronic diseases and aging.”

FRANK LONGO, M.D.

“The Palo Alto Longevity Prize has the potential to fundamentally impact humankind by unlocking the secrets to longevity and healthy aging.”

Amir-Rubin

“The answers we find with this prize could not only teach us how to enhance lifespan but more importantly brain function and human health in general.”

BEN BARRES, M.D., PH.D.

“Health extension needs to happen sooner rather than later. I, for one, do not want to be part of the last generation that only lived to an average of 80 years.”

SONIA ARRISON

“Prizes work. They attract the best minds to focus on a breakthrough, media to educate the public and the money necessary to support the innovators.”

KEITH POWERS

“For far too long aging research is undercapitalized and over promoted in non rigorous contexts. Its great to finally see an effort to foster cogent science.”

LAURA DEMING

“Heart rate variability is a powerful potential biomarker. This prize will attract the best and brightest to take on the full puzzle.”

NINA KJELLSON

“As a venture investor, I am super excited to meet future teams and the potential opportunities that could result from this prize.”

STEVE HERROD

WHY A PRIZE?

Incentive prizes work because they attract:

minds

Minds

Prizes attract the best minds to focus on finding solutions to a specific area of innovation. From researchers at universities, to startups, to small teams within larger companies, prizes create a target for innovators to try to solve. Prize purses, advanced market commitments, and the glory of winning helps “pull” innovation in a specific direction. By creating a new playing field, prizes also help pull everyone together toward the common goal.

media

Media

Everyone loves a competition and everyone loves heroes, especially the media! When crafted and produced well, incentive prizes are a great way to tell stories and to educate the public about the area of discovery. They also provide a wonderful medium to create heroes out of the hard-working teams that make it happen.

money

Money

Once you have the best minds in the world focusing on a breakthrough area, capital will follow. Angel investors, venture capital funds, and the venture arms of corporations are always looking for the next breakthrough area and teams to invest in. Prizes help unearth who those teams are, and what they are working on related to the prize, and other products, services and intellectual property that they might have that are not related to the prize.

WHY-PRIZES-WORK
  • Now is the time to launch this prize, because we have reached the point in science, where we really do have the opportunity to solve aging.

    Dr. Doris Taylor
  • The Palo Alto Prize enables us to attack moonshot problems

    Jin Lee
  • Give nature the tools and get out of the way

    Doris Taylor
  • We have the foundations that will allow us to live to 120 and we can do it.

    David Mendelowitz
  • The race against time is imminent. We need to act now

    David Mendelowitz
  • Every moment of our life is a race against time

    Jin Lee
  • The longer people live and the more productive they are the more they contribute to society

    Irving Zucker
  • We’ve reached a point in science where we really do have the opportunity to solve aging

    Doris Taylor
  • You never change things by fighting the existing reality. To change something, build a new model that makes the existing model obsolete.

    R. Buckminster Fuller
  • If you keep us in this room long enough, we will solve aging

    Dr. Doris Taylor
  • Give nature the tools and get out of the way.

    Dr. Doris Taylor
  • We have to reinvent ourselves to make progress

    Irving Zucker

ADVISORY BOARD

VICTOR DZAU, M.D.

VICTOR DZAU, M.D.

President of the Institute of Medicine

LeonardGuarente

LEONARD GUARENTE, Ph.D.

Director, Glenn Laboratory for the Science of Aging at MIT

stuart

Dr. STUART KIM, Ph.D

Professor, Depts. of Developmental Biology and Genetics

Stanford University Medical Center

David-Sinclair

DAVID SINCLAIR, Ph.D.

Professor, Genetics Dept. Harvard Medical School

JohnSedivy

JOHN SEDIVY Ph.D.

Brown Faculty, Department of Molecular Biology, Cell Biology, and Biochemistry

keithblackwell

KEITH BLACKWELL, M.D, Ph.D.

Principal Investigator, The Blackwell Lab at the Joslin Diabetes Center

IMG_0824

SUSAN PESCHIN

President and CEO

Alliance for Aging Research

Reiter1

RUSSEL J. REITER, Ph.D., Dr.H.C.MULT.

Professor of Cell Biology, UT Health Science Center

STEVE JURVETSON

STEVE JURVETSON

Managing Director, Draper Fisher Jurvetson

hidary-headshot

JACK HIDARY

Founder, Hidary Foundation

FRANK LONGO, M.D.

FRANK LONGO, M.D.

Professor and Chair, Department of Neurology and Neurological Sciences, Stanford University

CHARLES CHO, M.D.

CHARLES CHO, M.D.

Professor of Neurology and Neurosurgery, Stanford University

verdin

ERIC VERDIN, M.D.

Senior Investigator, Gladstone Institute of Virology and Immunology Professor, UCSF School of Medicine

Finished

KEVIN PERROTT

Executive Director – Mprize, Methuselah Foundation

Joon Yun, M.D.
Joon Yun, M.D. Benefactor of the Palo Alto Longevity Prize Joon is the President of Palo Alto Investors, LLC, founded in 1989 with $1 billion in assets under management invested in healthcare. Board certified in radiology, Dr. Yun served on the clinical staff at Stanford Hospital from 2000-2006. Dr. Yun received his Bachelor of Arts in biology from Harvard University and his Doctor of Medicine from Duke University School of Medicine.  He is a contributor to Forbes. Follow him on Twitter @DrJoonYun.
SONIA ARRISON

SONIA ARRISON

Author, 100 Plus

KEITH POWERS

KEITH POWERS

President, Engaged Partners (Frm. EVP of Strategy, X PRIZE Foundation)

GUY P. NOHRA

GUY P. NOHRA

Co-Founder and Managing Director, Alta Partners

REESE JONES

REESE JONES

Associate Founder, Singularity University; Trustee, Santa Fe Institute

FEDERICK J. DOTZLER

FEDERICK J. DOTZLER

Managing Director, De Novo Ventures

NINA KJELLSON

NINA KJELLSON

Managing Director, Interwest Ventures

LAURA DEMING

LAURA DEMING

Founder, Longevity Fund

STEVE HERROD

STEVE HERROD

Managing Director, General Catalyst Partners

STEVE VASSALLO

STEVE VASSALLO

General Partner, Foundation Capital

CAMI SAMUELS

CAMI SAMUELS

Managing Director, Versant Ventures

GARHENG KONG, M.D., MBA

GARHENG KONG, M.D., MBA

Managing General Partner, Sofinova Ventures

PATRICK ENRIGHT

PATRICK ENRIGHT

Founder and Managing Director, Longitude Capital

JIM GLASHEEN, PH.D.

JIM GLASHEEN, PH.D.

General Partner, Technology Partners

ROGER J. QUY, PH.D.

ROGER J. QUY, PH.D.

General Partner, Technology Partners

KEVIN STARR

KEVIN STARR

Partner, Third Rock Ventures Patrick-Enright

JOSH MAKOWER, M.D.

JOSH MAKOWER, M.D.

Founder and CEO, ExploraMed

KERRY DOLAN

KERRY DOLAN

Assistant Managing Editor, Forbes

AMIR RUBIN

AMIR RUBIN

President and CEO of Stanford Hospital & Clinic

BARBARA J. NATTERSON-HOROWITZ, M.D.

BARBARA J. NATTERSON-HOROWITZ, M.D.

Professor of Medicine, UCLA Division of Cardiology

DAN MOORE

DAN MOORE

President and CEO, Cyberonics, Inc.

GRAHAM SPENCER

GRAHAM SPENCER

General Partner, Google Ventures, Trustee, Santa Fe Institute

BOB HARRINGTON, M.D.

BOB HARRINGTON, M.D.

Chairman, Department of Medicine, Stanford University

DAVID ARRINGTON

DAVID ARRINGTON

Associate Vice Chancellor, University Relations, UC San Francisco

AUBREY DE GREY, MA, PH.D

AUBREY DE GREY, MA, PH.D

Ph.D, Chief Science Officer, SENS Foundation

ValterLongo

VALTER LONGO, PH.D.

Director, USC Longevity Institute

JEAN-JACQUES BIENAIME

JEAN-JACQUES BIENAIME

CEO, Biomarin

BEN BARRES, M.D., PH.D.

BEN BARRES, M.D., PH.D.

Chairman, Department of Neurobiology, Stanford University

FRANK FISCHER

FRANK FISCHER

President and CEO, Neuropace, Inc.

JAMES R. DOTY, M.D.

JAMES R. DOTY, M.D.

Professor of Neurosurgery, Stanford University Founder and Director of CCARE

Alan

ALAN GREENE, MD

Author, Pediatrician, Founding President of the Society of Participatory Medicine

BrianKennedy

BRIAN KENNEDY,PH.D.

CEO and President, The Buck Institute for Research on Aging

LEIGHTON READ, MD

LEIGHTON READ, M.D.

Venture Partner, Alloy Ventures

HOYOUNG HUH

HOYOUNG HUH

Managing Director, Konus Advisory Group

ALBERT CHA

ALBERT CHA

Managing Partner, Vivo Ventures

MICHAEL MCCULLOUGH, M.D.

MICHAEL MCCULLOUGH, M.D.

Principal, Capricorn Healthcare & Special Opportunities

JENNIFER ALDEN

JENNIFER ALDEN

Director, Digital Content Strategy, Palo Alto Investors

declercq_press

CASPER deCLERQ

Partner, Norwest Venture Partners

Charles-Warden-Headshot-262×300

CHARLES WARDEN

Managing Director, Versant Ventures

OLEG NODELMAN

OLEG NODELMAN

Managing Partner, EcoR1 Capital

STACEY CHANG

STACEY CHANG

Director, Healthcare Practice at IDEO

Wayne-Jonas

WAYNE B. JONAS, M.D.

President & CEO Samueli Institute

ABOUT US

The Palo Alto Prize is a newly established Silicon Valley-based initiative of the Race Against Time Foundation. The mission of the Palo Alto Prize is to encourage collaboration, foster innovation, and build a community to address the underlying causes of aging. In addition to the $1 million of cash prizes, the Palo Alto Prize is also working with a number of angel investors, venture capital firms, corporate venture arms, institutions and private foundations to provide access to additional capital to the teams during the competition. While the Palo Alto Prize will help facilitate introductions, all transactions and due diligence will be done privately between the teams and potential investors and philanthropists.

The Race Against Time (dba The Hero Science Foundation www.herosf.org) is a 501(c)(3) educational non-profit organization (Tax ID: 47-2823482) created to raise public awareness and financial support for basic biomedical research related to increasing our health span and defining the fundamental biological mechanisms that prevent age-related diseases and disabilities.

About the prize sponsor:

Dr. Joon Yun, M.D., is the President of Palo Alto Investors, LLC, founded in 1989 with over $2 billion in assets under management invested in healthcare and the founder of the Palo Alto Institute, a nonprofit think-tank that has been providing operational support for the Palo Alto Prize. Board certified in radiology, Dr. Yun served on the clinical staff at Stanford Hospital from 2000-2006. Dr. Yun received his Bachelor of Arts in biology from Harvard University and his Doctor of Medicine from Duke University School of Medicine. Learn more at DrJoonYun.com and follow him at @drjoonyun

PALO ALTO PRIZE – LAUNCH

Gallery

  • PaloAltoLaunching

    PaloAltoLaunching

  • PaloAltoLaunching

    PaloAltoLaunching

  • PaloAltoLaunching

    PaloAltoLaunching

  • PaloAltoLaunching

    PaloAltoLaunching

  • PaloAltoLaunching

    PaloAltoLaunching

  • PaloAltoLaunching

    PaloAltoLaunching

  • PaloAltoLaunching

    PaloAltoLaunching

  • PaloAltoLaunching

    PaloAltoLaunching

Go to Gallery